Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Feedback Inhibition

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multi-directional phototherapy vs. unidirectional phototherapy from below for severe neonatal jaundice: a randomized pilot trial in home phototherapy.

European journal of pediatrics·2026

Same author

ABO-Incompatible Platelet Transfusions and Mortality Risk in Patients With Intracranial Hemorrhage.

Neurosurgery·2026

Same author

Defective cerebrovascular development in mice lacking TFPI is restored by activated protein C.

Blood·2026

Same author

Genome-wide association of pica within a cohort of volunteer blood donors potentially implicates the gene encoding neuropeptide VF.

Transfusion·2026

Same author

Neonatal outcomes following maternal red cell transfusions prior to or at delivery.

Journal of perinatology : official journal of the California Perinatal Association·2026

Same author

Evaluation of a new commercial assay for the measurement of tissue factor activity of extracellular vesicles isolated from human plasma.

Research and practice in thrombosis and haemostasis·2025

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

Simple and Effective Procedure for Hemostasis in Mouse Arteries

Simple and Effective Procedure for Hemostasis in Mouse Arteries

Published on: November 28, 2025

Curbing an inhibitor for hemostasis.

Gary E Gilbert¹, Alan E Mast

¹VA Boston Healthcare System.

|May 21, 2011

Summary

A novel RNA polymer effectively stops severe bleeding caused by factor VIII antibodies. This innovative therapy bypasses normal clotting, activating the body's own procoagulant mechanisms for enhanced hemostasis.

Area of Science:

Hematology
Coagulation science
RNA therapeutics

Background:

Factor VIII antibodies cause severe bleeding disorders by inhibiting intrinsic pathway coagulation.
Current therapies often bypass the normal coagulation cascade, presenting treatment challenges.

Discussion:

Waters and colleagues introduce a novel RNA polymer with therapeutic potential.
This RNA polymer acts by inhibiting a specific factor that suppresses tissue factor.

Key Insights:

The RNA polymer successfully blocks an inhibitor of tissue factor.
This blockade unleashes endogenous procoagulant activity, effectively stopping bleeding.
The study demonstrates a new strategy for managing factor VIII inhibitor-associated bleeding.

More Related Videos

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Related Experiment Videos

Last Updated: Jun 1, 2026

Simple and Effective Procedure for Hemostasis in Mouse Arteries

Simple and Effective Procedure for Hemostasis in Mouse Arteries

Published on: November 28, 2025

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Outlook:

This research opens avenues for developing novel RNA-based hemostatic agents.
Further investigation into the clinical efficacy and safety of this RNA polymer is warranted.
The findings could lead to improved treatments for hemophilia A and other factor VIII inhibitor conditions.